Related Experiment Video

Updated: Mar 6, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Metabolic Pathway Inhibition in Liver Cancer

Ali Zarrinpar1

  • 11 Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

SLAS Technology
|March 18, 2017
PubMed

Insights

This study explores targeting liver cancer

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Biochemistry

Background:

  • Liver cancer exhibits distinct physiological and metabolic differences from normal liver tissue.
  • Current research primarily targets oncogenic signaling pathways, with less focus on metabolic alterations crucial for cancer growth.
  • The metabolic reprogramming in liver cancer presents a potential therapeutic vulnerability.

Purpose of the Study:

  • To investigate the potential of targeting altered metabolic pathways in liver cancer.
  • To determine if metabolic pathways in liver cancer are sufficiently distinct for developing targeted therapies.
  • To explore the synergy between targeting oncogenic signaling and metabolic vulnerabilities.

Main Methods:

  • Review of existing literature on liver cancer metabolism and signaling pathways.
  • Analysis of the physiological differences between cancerous and noncancerous liver cells.
  • Conceptual framework for developing metabolic modulators and combination therapies.

Main Results:

  • Liver cancer's altered metabolism is a key factor in its development and growth.
  • Significant metabolic differences exist between liver cancer and surrounding healthy tissue, suggesting therapeutic potential.
  • Oncogenic signaling pathways are intrinsically linked to the altered metabolism of liver cancer.

Conclusions:

  • Targeting the unique metabolic profile of liver cancer offers a promising therapeutic strategy.
  • Clinical studies on metabolic modulators are needed to assess feasibility and efficacy.
  • Combining therapies that target oncogenic signaling with metabolic interventions may enhance treatment outcomes.
  • Biomarkers for metabolic sensitivity are crucial for personalized liver cancer treatment.
Keywords:
automated biologygenomicsmolecular biologyproteomics

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

593
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

2.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
304
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
270
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
318